Journal of Multidisciplinary Applied Natural Science
Open Access Journal
Scopus CiteScore 2024
4.8
Calculated on 05 May, 2025
SJR 2024
0.31
Powered by scimagojr.com
Open Access Journal
4.8
Calculated on 05 May, 2025
0.31
Powered by scimagojr.com
https://doi.org/10.47352/jmans.2774-3047.231
Yehezkiel Steven Kurniawan
Hanif Amrulloh
Ervan Yudha
Nela Fatmasari
Faris Hermawan
Anggit Fitria
Harno Dwi Pranowo
Eti Nurwening Sholikhah
Jumina Jumina
Breast cancer is a severe global disease for women as the number of deaths increases annually. Therefore, attempts to find new anticancer agents are critical and inevitable. In this work, we report the investigation on the anticancer activity of xanthone and cinnamoylbenzene compounds against two breast cancer cell lines, i.e., T47D and MCF-7, through experimental in vitro and theoretical in silico assays. Xanthone and cinnamoylbenzene exhibit anticancer activity with a half-maximal inhibitory concentration (IC50) of 136.7–194.3 and 235.8–262.4 µg/mL against T47D and MCF-7 cancer cells, respectively. Cinnamoylbenzene generates less cytotoxicity to normal Vero cells with a selectivity index of 1.095–2.102. The molecular docking studies agree with the experimental data in which cinnamoylbenzene is more active against T47D with an IC50 of 136.7 µg/mL due to Topoisomerase II inhibition through π-π stacked interactions with Adenine12 and Guanine13 nitrogen bases. Meanwhile, xanthone is more active against MCF-7 with an IC50 of 235.8 µg/mL due to EGFR inhibition through van der Waals interaction and hydrogen bond with Glutamic acid767 and Methionine769 amino acid residues, respectively. Additionally, the pharmacokinetic parameters of xanthone and cinnamoylbenzene are predicted through absorption, distribution, metabolism, excretion, and toxicity (ADMET) analysis, and they show better suitability than doxorubicin as the commercial anticancer drug.
[1] N. Harbeck, F. Penault-Llorca, J. Cortes, M. Gnant, N. Houssami, P. Poortmans, K. Ruddy, J. Tsang, and F. Cardoso. (2019). "Breast cancer". Nature Reviews Disease Primers. 5 (1): 66. 10.1038/s41572-019-0111-2.
[2] Y. S. Kurniawan, K. Gurning, I. Iksen, and A. Bikharudin. (2024). "Fight for Cancer Diseases using Natural Compounds and Their Semisynthetic Derivatives". Bioactivities. 10.47352/bioactivities.2963-654X.221.
[3] S. Lukasiewicz, M. Czeczelewski, A. Forma, J. Baj, R. Sitarz, and A. Stanislawek. (2021). "Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review". Cancers (Basel).13 (17). 10.3390/cancers13174287.
[4] R. L. Siegel, A. N. Giaquinto, and A. Jemal. (2024). "Cancer statistics, 2024". Ca-A Cancer Journal for Clinicians. 74 (1): 12-49. 10.3322/caac.21820.
[5] K. Gurning, S. Suratno, E. Astuti, and W. Haryadi. (2024). "Untargeted LC/HRMS Metabolomics Analysis and Anticancer Activity Assay on MCF-7 and A549 Cells from Coleus amboinicus Lour Leaf Extract". Iranian Journal of Pharmaceutical Research. 23 (1): e143494. 10.5812/ijpr-143494.
DOI: https://doi.org/10.5812/ijpr-143494[6] B. Smolarz, A. Z. Nowak, and H. Romanowicz. (2022). "Breast Cancer-Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature)". Cancers (Basel). 14 (10). 10.3390/cancers14102569.
[7] R. Hong and B. Xu. (2022). "Breast cancer: an up-to-date review and future perspectives". Cancer Communications (London). 42 (10): 913-936. 10.1002/cac2.12358.
[8] S. Yu, T. Kim, K. H. Yoo, and K. Kang. (2017). "The T47D cell line is an ideal experimental model to elucidate the progesterone-specific effects of a luminal A subtype of breast cancer". Biochemical and Biophysical Research Communications. 486 (3): 752-758. 10.1016/j.bbrc.2017.03.114.
[9] M. Zubair, S. Wang, and N. Ali. (2020). "Advanced Approaches to Breast Cancer Classification and Diagnosis". Frontiers in Pharmacology. 11 : 632079. 10.3389/fphar.2020.632079.
[10] P. Rameshwar, J. A. Aka, and S.-X. Lin. (2012). "Correction: Comparison of Functional Proteomic Analyses of Human Breast Cancer Cell Lines T47D and MCF7". PLoS ONE. 7 (4). 10.1371/annotation/18f08a33-35e1-4bf9-8d21-476757dccbef.
[11] Z. Skok, N. Zidar, D. Kikelj, and J. Ilas. (2020). "Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets". Journal of Medicinal Chemistry. 63 (3): 884-904. 10.1021/acs.jmedchem.9b00726.
[12] O. Troitskaya, D. Novak, A. Nushtaeva, M. Savinkova, M. Varlamov, M. Ermakov, V. Richter, and O. Koval. (2021). "EGFR Transgene Stimulates Spontaneous Formation of MCF7 Breast Cancer Cells Spheroids with Partly Loss of HER3 Receptor". International Journal of Molecular Sciences. 22 (23). 10.3390/ijms222312937.
DOI: https://doi.org/10.3390/ijms222312937[13] E. Y. Chen, V. Raghunathan, and V. Prasad. (2019). "An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate". JAMA Internal Medicine. 179 (7): 915-921. 10.1001/jamainternmed.2019.0583.
[14] S. Ratnani and S. Malik. (2022). "Therapeutic Properties of Green Tea: A Review". Journal of Multidisciplinary Applied Natural Science. 2 (2): 90-102. 10.47352/jmans.2774-3047.117.
[15] Y. S. Kurniawan, T. Indriani, H. Amrulloh, L. C. Adi, A. C. Imawan, K. T. A. Priyangga, and E. Yudha. (2023). "Journey of Natural Products: From Isolation Stage to Drug’s Approval in Clinical Trials". Bioactivities. 1 (2): 43-60. 10.47352/bioactivities.2963-654X.190.
DOI: https://doi.org/10.47352/bioactivities.2963-654X.190[16] Y. S. Kurniawan, N. Fatmasari, H. D. Pranowo, E. N. Sholikhah, and J. Jumina. (2024). "Investigation on anticancer agent against cervical and colorectal cancer cell lines: One-pot synthesis, in vitro and in silico assays of xanthone derivatives". Journal of Applied Pharmaceutical Science. 10.7324/japs.2024.160049.
[17] D. R. P. Loureiro, J. X. Soares, J. C. Costa, A. F. Magalhaes, C. M. G. Azevedo, M. M. M. Pinto, and C. M. M. Afonso. (2019). "Structures, Activities and Drug-Likeness of Anti-Infective Xanthone Derivatives Isolated from the Marine Environment: A Review". Molecules. 24 (2). 10.3390/molecules24020243.
[18] M. M. M. Pinto, A. Palmeira, C. Fernandes, D. Resende, E. Sousa, H. Cidade, M. E. Tiritan, M. Correia-da-Silva, and S. Cravo. (2021). "From Natural Products to New Synthetic Small Molecules: A Journey through the World of Xanthones". Molecules. 26 (2). 10.3390/molecules26020431.
[19] A. Rammohan, J. S. Reddy, G. Sravya, C. N. Rao, and G. V. Zyryanov. (2020). "Chalcone synthesis, properties and medicinal applications: a review". Environmental Chemistry Letters. 18 (2): 433-458. 10.1007/s10311-019-00959-w.
[20] Y. S. Kurniawan, K. T. A. Priyangga, Jumina, H. D. Pranowo, E. N. Sholikhah, A. K. Zulkarnain, H. A. Fatimi, and J. Julianus. (2021). "An Update on the Anticancer Activity of Xanthone Derivatives: A Review". Pharmaceuticals (Basel). 14(11). 10.3390/ph14111144.
[21] P. S. de Souza, G. C. C. Biba, E. Melo, and M. F. Muzitano. (2022). "Chalcones against the hallmarks of cancer: a mini-review". Natural Product Research. 36 (18): 4809-4826. 10.1080/14786419.2021.2000980.
[22] N. Fatmasari, Y. S. Kurniawan, J. Jumina, C. Anwar, Y. Priastomo, H. D. Pranowo, A. K. Zulkarnain, and E. N. Sholikhah. (2022). "Synthesis and in vitro assay of hydroxyxanthones as antioxidant and anticancer agents". Scientific Reports. 12 (1): 1535. 10.1038/s41598-022-05573-5.
[23] A. A. Tri Suma, T. Dwi Wahyuningsih, and Mustofa. (2019). "Efficient Synthesis of Chloro Chalcones under Ultrasound Irradiation, Their Anticancer Activities and Molecular Docking Studies". Rasayan Journal of Chemistry. 12 (02): 502-510. 10.31788/rjc.2019.1225020.
DOI: https://doi.org/10.31788/RJC.2019.1225020[24] M. Ghasemi, T. Turnbull, S. Sebastian, and I. Kempson. (2021). "The MTT Assay: Utility, Limitations, Pitfalls, and Interpretation in Bulk and Single-Cell Analysis". International Journal of Molecular Sciences. 22 (23). 10.3390/ijms222312827.
[25] D. Ramirez and J. Caballero. (2018). "Is It Reliable to Take the Molecular Docking Top Scoring Position as the Best Solution without Considering Available Structural Data?". Molecules. 23 (5). 10.3390/molecules23051038.
[26] P. Kumar, A. Nagarajan, and P. D. Uchil. (2018). "Analysis of Cell Viability by the MTT Assay". Cold Spring Harbor Protocols. 2018 (6). 10.1101/pdb.prot095505.
[27] H. Yu, D. J. Kim, H. Y. Choi, S. M. Kim, M. I. Rahaman, Y. H. Kim, and S. W. Kim. (2021). "Prospective pharmacological methodology for establishing and evaluating anti-cancer drug resistant cell lines". BMC Cancer. 21 (1): 1049. 10.1186/s12885-021-08784-7.
[28] O. Tacar, P. Sriamornsak, and C. R. Dass. (2013). "Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems". Journal of Pharmacy and Pharmacology. 65 (2): 157-70. 10.1111/j.2042-7158.2012.01567.x.
[29] J. J. Lica, M. Wieczor, G. J. Grabe, M. Heldt, M. Jancz, M. Misiak, K. Gucwa, W. Brankiewicz, N. Maciejewska, A. Stupak, M. Baginski, K. Rolka, A. Hellmann, and A. Skladanowski. (2021). "Effective Drug Concentration and Selectivity Depends on Fraction of Primitive Cells". International Journal of Molecular Sciences. 22 (9). 10.3390/ijms22094931.
DOI: https://doi.org/10.3390/ijms22094931[30] J. L. Nitiss. (2009). "Targeting DNA topoisomerase II in cancer chemotherapy". Nature Reviews Cancer. 9 (5): 338-50. 10.1038/nrc2607.
[31] M. L. Uribe, I. Marrocco, and Y. Yarden. (2021). "EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance". Cancers (Basel). 13 (11). 10.3390/cancers13112748.
[32] J. Stamos, M. X. Sliwkowski, and C. Eigenbrot. (2002). "Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor". Journal of Biological Chemistry. 277 (48): 46265-72. 10.1074/jbc.M207135200.
[33] Y. S. Kurniawan, E. Yudha, G. Nugraha, N. Fatmasari, H. D. Pranowo, J. Jumina, and E. N. Sholikhah. (2024). "Molecular Docking and Molecular Dynamic Investigations of Xanthone-Chalcone Derivatives against Epidermal Growth Factor Receptor for Preliminary Discovery of Novel Anticancer Agent". Indonesian Journal of Chemistry. 24 (1). 10.22146/ijc.88449.
DOI: https://doi.org/10.22146/ijc.88449[34] K. Lemke, M. Wojciechowski, W. Laine, C. Bailly, P. Colson, M. Baginski, A. K. Larsen, and A. Skladanowski. (2005). "Induction of unique structural changes in guanine-rich DNA regions by the triazoloacridone C-1305, a topoisomerase II inhibitor with antitumor activities". Nucleic Acids Research. 33 (18): 6034-47. 10.1093/nar/gki904.
[35] B. Tylinska, A. Dobosz, J. Spychala, L. Cwynar-Zajac, Z. Czyznikowska, A. Kuzniarski, and T. Gebarowski. (2021). "Evaluation of Interactions of Selected Olivacine Derivatives with DNA and Topoisomerase II". International Journal of Molecular Sciences. 22 (16). 10.3390/ijms22168492.
[36] Y. S. Kurniawan, N. Fatmasari, J. Jumina, H. D. Pranowo, and E. N. Sholikhah. (2023). "Evaluation of The Anticancer Activity of Hydroxyxanthones Against Human Liver Carcinoma Cell Line". Journal of Multidisciplinary Applied Natural Science. 4 (1): 1-15. 10.47352/jmans.2774-3047.165.
[37] D. E. Pires, T. L. Blundell, and D. B. Ascher. (2015). "pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures". Journal of Medicinal Chemistry. 58 (9): 4066-72. 10.1021/acs.jmedchem.5b00104.
[38] C. A. Lipinski, F. Lombardo, B. W. Dominy, and P. J. Feeney. (2001). "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings". Advanced Drug Delivery Reviews. 46 (1-3): 3-26. 10.1016/s0169-409x(00)00129-0.
[39] S. Vilar, M. Chakrabarti, and S. Costanzi. (2010). "Prediction of passive blood-brain partitioning: straightforward and effective classification models based on in silico derived physicochemical descriptors". Journal of Molecular Graphics and Modelling. 28 (8): 899-903. 10.1016/j.jmgm.2010.03.010.
[40] G. Damodar, T. Smitha, S. Gopinath, S. Vijayakumar, and Y. Rao. (2014). "An evaluation of hepatotoxicity in breast cancer patients receiving injection Doxorubicin". Annals of Medical and Health Science Research. 4 (1): 74-9. 10.4103/2141-9248.126619.
[41] A. Pugazhendhi, T. Edison, B. K. Velmurugan, J. A. Jacob, and I. Karuppusamy. (2018). "Toxicity of Doxorubicin (Dox) to different experimental organ systems". Life Sciences. 200 : 26-30. 10.1016/j.lfs.2018.03.023.
[42] A. N. Linders, I. B. Dias, T. Lopez Fernandez, C. G. Tocchetti, N. Bomer, and P. Van der Meer. (2024). "A review of the pathophysiological mechanisms of doxorubicin-induced cardiotoxicity and aging". NPJ Aging. 10 (1): 9. 10.1038/s41514-024-00135-7.
[43] K. Renu, L. P. Pureti, B. Vellingiri, and A. Valsala Gopalakrishnan. (2021). "Toxic effects and molecular mechanism of doxorubicin on different organs – an update". Toxin Reviews. 41 (2): 650-674. 10.1080/15569543.2021.1912099.
